Everolimus is an mTOR inhibitor that can be used in metastatic insulinoma due to its antiproliferative activity and desirable side effect of hyperglycaemia mediated through impaired peripheral glucose uptake, impaired beta cell insulin secretion and increased hepatic gluconeogenesis (Hofland et al. 2023). This evidence concerns the gene INS and Hyperglycemia.